>
細(xì)胞CELL>
ATCC普通細(xì)胞>
CHO/dhFr- [CHO duk-, NOTE: dhfr refers to dihydrofolate reductase]
細(xì)胞形態(tài):上皮樣
是否是腫瘤細(xì)胞:0
物種來源:倉(cāng)鼠
ATCC Number:CRL-9096?
相關(guān)疾?。赫?br />
器官來源:卵巢
數(shù)量:大量
生長(zhǎng)狀態(tài):貼壁生長(zhǎng)
運(yùn)輸方式:凍存運(yùn)輸
規(guī)格:0.1ml Designations: CHO/dhFr- [CHO duk-, NOTE: dhfr refers to dihydrofolate reductase]
Depositors: ?Hoffmann-La Roche Ltd.
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Cricetulus griseus
Morphology:epithelial
Source: Organ: ovary
Disease: normal
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:transfection host (Roche Transfection Reagents )
Gender: female
Propagation: ATCC complete growth medium: Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and supplemented with 0.1 mM hypoxanthine, 0.016 mM thymidine, 0.002mM Methotrexate (Amethopterin) and 10% fetal bovine serum
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0℃
Growth Conditions: The cells are deficient in dihydrofolate reductase.They should die in the absence of HT ( Hypoxanthine-Thymidine). Methotrexate (Amethopterin) is added to the cell culture medium to prevent growth of revertant cells with a low resistance to the drug.
Subculturing: Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
Medium additive:ATCC 71-X
References: 26539: Shulman T, et al. An antibody reactive with domain 4 of the platelet-derived growth factor beta receptor allows BB binding while inhibiting proliferation by impairing receptor dimerization. J. Biol. Chem. 272: 17400-17404, 1997. PubMed: 9211881
30382: Morel-Kopp MC, et al. A three amino acid deletion in glycoprotein IIIa is responsible for type I glanzmann's thrombasthenia: importance of residues I1e325Pro326Gly327 for beta 3 integrin subunit association. Blood 90: 669-677, 1997. PubMed: 9226167
30522: Libyh MT, et al. A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein. Blood 90: 3978-3983, 1997. PubMed: 9354666